19 results
PRE 14A
ATHA
Athira Pharma Inc
28 Mar 24
Preliminary proxy
8:47am
to December 2017. During his tenure as chief financial officer at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private … , business acumen, proven achievement and competence in one’s field, the ability to exercise sound business judgment, tenure on the board of directors
DFAN14A
EX-99.1
ATHA
Athira Pharma Inc
25 Apr 22
Additional proxy materials by non-management
3:31pm
is to clearly message the Company’s mission and goals.
Following the partial rebound, under Dr. Mark Litton’s tenure as President & CEO and until the public … Mark Litton Director Barbara Kosacz
Why Dr. Litton is Not the Right Candidate 29 Tenure: Only 2 years at Athira prior to becoming CEO.Inconsistency
DFAN14A
EX-99.5
Kayne Richard A
22 Apr 22
Additional proxy materials by non-management
10:07am
Athira through this critical chapter. To date, the Board has been built by balancing the benefits of tenure and experience with the need for fresh
DFAN14A
EX-99.6
geadbs8o
22 Apr 22
Additional proxy materials by non-management
10:07am
DEFC14A
v79acd5mdi4b17ijt8wt
5 Apr 22
Proxy in contested solicitation
4:08pm
PREC14A
kio2 0qxv
25 Mar 22
Preliminary proxy with contested solicitation
5:15pm
DEF 14A
cn5y2 ssaqj
16 Apr 21
Definitive proxy
6:02am
10-K
83pki
25 Mar 21
Annual report
12:00am
8-K
EX-99.1
m5l43w x4079
8 Mar 21
Athira Pharma Announces Appointment of Barbara Kosacz
7:05am
424B4
sbd6u
21 Jan 21
Prospectus supplement with pricing info
12:00am
DRS
wqqic3 nh
6 Jan 21
Draft registration statement
12:00am
424B4
1aumitx5
18 Sep 20
Prospectus supplement with pricing info
4:05pm
S-1
cgbsztzw
26 Aug 20
IPO registration
5:25pm
DRS
mqjnrl2ehqhsb
24 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next